Contact
searchSearch
HMP Global
Login

News

News
Transdermal Estradiol Noninferior to LHRH Agonists in Locally Advanced Prostate Cancer
04/01/2026
Stephanie Holland
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study...
04/01/2026
Oncology
News
FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute
News
FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute
Mustafa Basree, DO, University of Wisconsin
Videos
Personalized Dosimetry Guides 177Lu-PSMA-617 Therapy in Prostate Cancer
02/06/2026
Mustafa Basree, DO
Mustafa Basree, DO, discusses institutional experience using voxel-level, patient-specific dosimetry to personalize 177Lu-PSMA-617 dosing in patients with metastatic castration-resistant prostate cancer.
Mustafa Basree, DO, discusses institutional experience using voxel-level, patient-specific dosimetry to personalize 177Lu-PSMA-617 dosing in patients with metastatic castration-resistant prostate cancer.
Mustafa Basree, DO, discusses...
02/06/2026
Radiopharmaceutical Education Institute
Mustafa Basree, DO, University of Wisconsin
Videos
Personalized Dosimetry Guides 177Lu-PSMA-617 Therapy in Prostate Cancer
02/06/2026
Mustafa Basree, DO
Mustafa Basree, DO, discusses institutional experience using voxel-level, patient-specific dosimetry to personalize 177Lu-PSMA-617 dosing in patients with metastatic castration-resistant prostate cancer.
Mustafa Basree, DO, discusses institutional experience using voxel-level, patient-specific dosimetry to personalize 177Lu-PSMA-617 dosing in patients with metastatic castration-resistant prostate cancer.
Mustafa Basree, DO, discusses...
02/06/2026
Radiopharmaceutical Education Institute
FDA Approval
FDA Approves Rucaparib for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
12/17/2025
Stephanie Holland
Based on results from the TRITON3 study, the FDA granted approval to rucaparib for previously treated patients with deleterious BRCA mutation-associated metastatic castration-resistant prostate cancer.
Based on results from the TRITON3 study, the FDA granted approval to rucaparib for previously treated patients with deleterious BRCA mutation-associated metastatic castration-resistant prostate cancer.
Based on results from the...
12/17/2025
Oncology
News
Leuprolide Drives Significantly Higher Coronary Plaque Growth vs Relugolix in Patients With Prostate Cancer
12/16/2025
Stephanie Holland
Updated results from the REVELUTION trial show that androgen deprivation therapy with leuprolide leads to significantly greater coronary plaque progression than relugolix in patients with prostate cancer.
Updated results from the REVELUTION trial show that androgen deprivation therapy with leuprolide leads to significantly greater coronary plaque progression than relugolix in patients with prostate cancer.
Updated results from the...
12/16/2025
Oncology
News
177Lu-PSMA-617 Added to Standard of Care Improves Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer
10/19/2025
Stephanie Holland
Adding 177Lu-PSMA-617 to standard androgen deprivation therapy plus an androgen receptor pathway inhibitor significantly improved radiographic PFS in metastatic hormone-sensitive prostate cancer, according to a second interim analysis from...
Adding 177Lu-PSMA-617 to standard androgen deprivation therapy plus an androgen receptor pathway inhibitor significantly improved radiographic PFS in metastatic hormone-sensitive prostate cancer, according to a second interim analysis from...
Adding 177Lu-PSMA-617 to...
10/19/2025
Radiopharmaceutical Education Institute
News
177Lu-PSMA-617 Added to Standard of Care Improves Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer
10/19/2025
Stephanie Holland
Adding 177Lu-PSMA-617 to standard androgen deprivation therapy plus an androgen receptor pathway inhibitor significantly improved radiographic PFS in metastatic hormone-sensitive prostate cancer, according to a second interim analysis from...
Adding 177Lu-PSMA-617 to standard androgen deprivation therapy plus an androgen receptor pathway inhibitor significantly improved radiographic PFS in metastatic hormone-sensitive prostate cancer, according to a second interim analysis from...
Adding 177Lu-PSMA-617 to...
10/19/2025
Radiopharmaceutical Education Institute
News
Cabozantinib Plus Atezolizumab Demonstrates Promise Among Patients With Metastatic Castration-Resistant Prostate Cancer and Soft-Tissue Metastases
08/19/2025
Stephanie Holland
According to results from the ongoing, phase 3 CONTACT-02 trial, cabozantinib plus atezolizumab demonstrated promise among patients with metastatic castration-resistant prostate cancer and soft-tissue metastases who experienced disease...
According to results from the ongoing, phase 3 CONTACT-02 trial, cabozantinib plus atezolizumab demonstrated promise among patients with metastatic castration-resistant prostate cancer and soft-tissue metastases who experienced disease...
According to results from the...
08/19/2025
Oncology

Recent News

News
Sintilimab Plus Anlotinib Demonstrates Promise in Relapsed/Refractory Small Cell Lung Cancer
04/02/2026
Stephanie Holland
Results from a phase 2 trial suggest that sintilimab plus anlotinib demonstrates encouraging efficacy with manageable safety among patients with relapsed/refractory small cell lung cancer (SCLC) who have a short chemotherapy-free...
Results from a phase 2 trial suggest that sintilimab plus anlotinib demonstrates encouraging efficacy with manageable safety among patients with relapsed/refractory small cell lung cancer (SCLC) who have a short chemotherapy-free...
Results from a phase 2 trial...
04/02/2026
Oncology
News
Adebrelimab Plus Chemotherapy Maintains Long-Term Survival Benefit in ES-SCLC
04/02/2026
Stephanie Holland
Updated results from the phase 3 CAPSTONE-1 trial demonstrate that adebrelimab plus chemotherapy continues to provide durable survival benefit in patients with extensive-stage small cell lung cancer.
Updated results from the phase 3 CAPSTONE-1 trial demonstrate that adebrelimab plus chemotherapy continues to provide durable survival benefit in patients with extensive-stage small cell lung cancer.
Updated results from the phase 3...
04/02/2026
Oncology
News
Lurbinectedin Plus Atezolizumab Delays Subsequent Therapy and Maintains Survival Benefit in ES-SCLC
04/02/2026
Stephanie Holland
Exploratory results from the phase 3 IMforte trial suggest that first-line treatment with lurbinectedin plus atezolizumab delays subsequent therapy and maintains overall survival benefit in patients with extensive-stage small cell lung cancer.
Exploratory results from the phase 3 IMforte trial suggest that first-line treatment with lurbinectedin plus atezolizumab delays subsequent therapy and maintains overall survival benefit in patients with extensive-stage small cell lung cancer.
Exploratory results from the...
04/02/2026
Oncology
FDA Approval
FDA Approves Brexucabtagene Autoleucel for R/R Mantle Cell Lymphoma
04/02/2026
Stephanie Holland
Based on results from the phase 2 ZUMA-2 study, the FDA approved brexucabtagene autoleucel for adult patients with relapsed/refractory mantle cell lymphoma, including those who are BTK inhibitor–naïve.
Based on results from the phase 2 ZUMA-2 study, the FDA approved brexucabtagene autoleucel for adult patients with relapsed/refractory mantle cell lymphoma, including those who are BTK inhibitor–naïve.
Based on results from the phase...
04/02/2026
Oncology
News
Consolidation Serplulimab Following Hypo-cCRT Improves Outcomes in Limited-Stage Small Cell Lung Cancer
04/02/2026
Emily Estrada
Updated results from the phase 2 ASTRUM-LC01 trial demonstrate that following concurrent Hypo-cCRT with consolidation serplulimab improves survival with manageable safety in limited-stage small cell lung cancer.
Updated results from the phase 2 ASTRUM-LC01 trial demonstrate that following concurrent Hypo-cCRT with consolidation serplulimab improves survival with manageable safety in limited-stage small cell lung cancer.
Updated results from the phase 2...
04/02/2026
Oncology
News
Izalontamab Brengitecan Plus Serplulimab Demonstrates Strong Promise in Treatment-Naïve ES-SCLC
04/01/2026
Emily Estrada
According to results from the phase 2 BL-B01D1-204-01 study, izalontamab brengitecan plus serplulimab demonstrated encouraging efficacy with manageable safety in treatment- extensive-stage small cell lung cancer.
According to results from the phase 2 BL-B01D1-204-01 study, izalontamab brengitecan plus serplulimab demonstrated encouraging efficacy with manageable safety in treatment- extensive-stage small cell lung cancer.
According to results from the...
04/01/2026
Oncology
News
Transdermal Estradiol Noninferior to LHRH Agonists in Locally Advanced Prostate Cancer
04/01/2026
Stephanie Holland
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study...
04/01/2026
Oncology
News
Etrumadenant-Based Chemoimmunotherapy Improves Survival in Metastatic Colorectal Cancer
04/01/2026
Emily Estrada
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9...
04/01/2026
Oncology
News
Distinct Immune Microenvironment Associated With Long-Term Survival in High-Grade Glioma
03/31/2026
Emily Estrada
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational...
03/31/2026
Oncology
News
Ruxolitinib Plus Venetoclax Demonstrates Safe but Limited Clinical Activity in Relapsed/Refractory AML
03/31/2026
Emily Estrada
Results from a multicenter, phase 1 trial demonstrated that ruxolitinib plus venetoclax is well tolerated but shows modest clinical activity in heavily pretreated relapsed/refractory acute myeloid leukemia.
Results from a multicenter, phase 1 trial demonstrated that ruxolitinib plus venetoclax is well tolerated but shows modest clinical activity in heavily pretreated relapsed/refractory acute myeloid leukemia.
Results from a multicenter,...
03/31/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use